8-K/A: RxSight Amends CFO Compensation, Vesting Details
Amendment to Current Report
RxSight, Inc. filed an amended 8-K to disclose the exact sign-on bonus amount and correct the stock option vesting schedule for its Chief Financial Officer, Mark Wilterding.
Summary
- RxSight, Inc. filed an amended Current Report on Form 8-K/A to update information regarding its Chief Financial Officer, Mark Wilterding.
- The amendment discloses the specific amount of Mr. Wilterding's sign-on bonus, which was determined to be $169,348.10 on March 10, 2026.
- The sign-on bonus was subsequently paid to Mr. Wilterding on March 13, 2026, after applicable deductions.
- The filing also corrects the vesting schedule for Mr. Wilterding's stock option.
- The corrected vesting schedule states that 25% of the shares subject to the option will vest on the one-year anniversary of January 11, 2026, with the remaining balance vesting equally monthly over the subsequent three years, leading to full vesting four years from January 11, 2026, contingent on continued employment.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative update, providing necessary clarification on executive compensation without indicating any operational or strategic shifts.
Positives
- Clarification of executive compensation details provides transparency.
Negatives
- Initial filing required an amendment, indicating a minor administrative oversight in the initial disclosure.
Future Outlook
The filing outlines the vesting schedule for the CFO's stock options, indicating a four-year commitment period for full vesting, subject to continued employment.
Industry Context
StockSavvy.ai notes that amendments to executive compensation details are common administrative updates in SEC filings, reflecting the ongoing process of finalizing employment terms. This filing does not provide broader industry insights.
Comparison to Industry Standards
- This filing is an administrative update regarding executive compensation. StockSavvy.ai finds no direct comparable companies, projects, or results within this specific filing to assess against global benchmarks.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Financial Officer | N/A | Mark Wilterding | 2026-01-11 | Appointment (compensation details amended in this filing) |
Stakeholder Impact
- Shareholders: Provides clarity on executive compensation, which contributes to corporate transparency.
- Employees: No direct impact on general employees, but clarifies compensation structure for a key executive.
Next Steps
- Continued employment of Mark Wilterding as Chief Financial Officer.
- Ongoing vesting of Mark Wilterding's stock options over the next four years, contingent on continued employment.
Key Dates
| Date | Description |
|---|---|
| 2025-12-15 | Date of confirmatory employment letter with Mark Wilterding. |
| 2026-01-11 | Effective date of Mark Wilterding's employment as CFO and start of option vesting period. |
| 2026-01-12 | Date RxSight, Inc. filed the Initial Report on Form 8-K regarding CFO appointment. |
| 2026-03-10 | Date Mark Wilterding's sign-on bonus amount was determined to be $169,348.10. |
| 2026-03-13 | Date the sign-on bonus was paid to Mark Wilterding. |
| 2026-03-19 | Date of filing this Current Report on Form 8-K/A. |
Keywords
RxSight, CFO compensation, Mark Wilterding, sign-on bonus, stock option vesting, SEC filing, 8-K/A, executive compensation, corporate governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.